Epitope placement tunes CSF tau biomarkers: Comparison of P-tau217 and BD-tau designs

Background

Measurement of different tau species using immunoassays has proven effective for detecting early Alzheimer's disease (AD) pathology. However, assay performance depends on factors such as the tau form targeted (phosphorylated or non-phosphorylated) and the partner antibody used. Here, we evaluated five different antibody combinations for their ability to differentiate amyloid-positive (Aβ +) from amyloid-negative (Aβ -) individuals in cerebrospinal fluid (CSF).